When patients with suboptimally-controlled diabetes switched from prior anti-hyperglycemic regimens to basal-bolus insulin therapy using V-Go, there was a statistically significant reduction in A1C as well as a significant improvement in patients achieving an A1C goal of < 8%. This evidence concerns the gene INS and diabetes mellitus.